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Abstract
Background and objective: With prolonged use of anabolic androgenic steroids (AAS), occasional incidents of renal 
disorders have been observed. Independently, it has also been established that there are considerable inter-individual 
and inter-ethnic differences, in particular with reference to the uridine diphosphate-glucuronosyltransferase 2B17 
(UGT2B17) gene, in metabolising these compounds. This report postulates the association of deletion polymorphism in 
the UGT2B17 gene with the occurrence of renal disorders on chronic exposure to AAS.
Presentation of the hypothesis: The major deactivation and elimination pathway of AASs is through glucuronide 
conjugation, chiefly catalyzed by the UGT2B17 enzyme, followed by excretion in urine. Excretion of steroids is affected 
in individuals with a deletion mutation in the UGT2B17 gene. We hypothesize that UGT2B17 deficient individuals are 
more vulnerable to developing renal disorders with prolonged use of AAS owing to increases in body mass index and 
possible direct toxic effects of steroids on the kidneys. Elevated serum levels of biologically active steroids due to 
inadequate elimination can lead to prolonged muscle build up. An increase in body mass index may cause renal 
injuries due to sustained elevated glomerular pressure and flow rate.
Testing the hypothesis: In the absence of controlled clinical trials in humans, observational studies can be carried out. 
Real time PCR with allelic discrimination should be employed to examine the prevalence of different UGT2B17 
genotypes in patients with impaired renal function and AAS abuse. In individuals with the UGT2B17 deletion 
polymorphism, blood tests, biofluid analyses, urinalysis, and hair analyses following the administration of an anabolic 
steroid can be used to determine the fate of the substance once in the body.
Implications of the hypothesis: If the hypothesis is upheld, anabolic steroid users with a deletion mutation in the 
UGT2B17 gene may be exposed to an increased risk of developing renal disorders. In the current detecting - 
sanctioning anti-doping system, athletes motivated by the potential to evade detection owing to their unique genetic 
make-up could subject themselves to a serious health consequence. More research on AAS metabolism in the 
presence of UGT2B17 gene deletion is required. Benefit - harm evaluations in therapeutic use of anabolic steroids 
should also consider this potential link between UGT2B17 gene deletion polymorphism and renal disorders.
Background
"The purposes of the World Anti-Doping Code and the
World Anti-Doping Program which supports it are: i) to
protect the Athletes' fundamental right to participate in
doping-free sport and thus promote health, fairness and
equality for Athletes worldwide, and ii) to ensure harmo-
nized, coordinated and effective anti-doping programs at
the international and national level with regard to detec-
tion, deterrence and prevention of doping" [1]. Current
doping control is primarily based on enforcement, com-
plemented by deterrence strategies. Meticulously regu-
lated testing protocols, including regulated analytical
testing in accredited laboratories and international stan-
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doping rules worldwide and to deter others from doing so
[2,3]. The use of performance-enhancing substances and
methods deemed to be prohibited is an anti-doping rule
violation that is established by the presence of a prohib-
ited substance or its metabolites or markers in the ath-
lete's sample, typically urine or blood [1].
Aside from an ongoing ethical debate on various facets
of doping [4], including moral reasoning [5] and medical
ethics [6-9], recent critical analyses of the current anti-
doping approach have claimed that the current anti-dop-
ing is not fit for purpose [10-13]. Reasons for this criti-
cism encompassed ethical issues around constant
surveillance [14,15], analytical difficulties and costs
[16,17], as well as marked inter-individual differences
[18-20].
Anabolic androgenic steroids (AASs) are synthetic
derivatives of the endogenously produced male sex hor-
mone, testosterone, which exhibits both anabolic (protein
synthesizing) and androgenic (masculinising) effects. Ste-
roids are one of the most potent and the most widely used
performance-enhancing substances both amongst Olym-
pic athletes [21-23] and also those outside of the auspices
of the World Anti-Doping Agency (WADA), such as
competitive and recreational body builders, professional
players or even non-athlete adolescent boys [24,25]. The
use of AASs is widespread particularly amongst athletes
because such drugs can improve their performance in
sports by accelerating muscle growth, increasing aggres-
siveness and enhancing a sense of well-being. Chronic
use of AASs has been known to cause serious adverse
effects such as virilization, feminization, liver disorders,
neuropsychiatric disorders, adverse blood lipid profiles
(increased LDL and decreased HDL), cardiovascular dis-
orders and renal complications [26-28]. Among these,
renal diseases have received less attention, most likely
because renal disorders are infrequent among AAS users
in comparison to other, more prevalent diseases.
Throughout the last decade, the literature sporadically
presented cases of severe renal disorders among AASs
users, especially with elevated and prolonged use [29-34].
The number of incidents presented is well below the esti-
mated number of AAS users, however, the user profiles
described in these case studies do not differ significantly
from those AASs abusers who do not develop renal com-
plications. Thus, there may be a connection between
deletion mutation in a steroid conjugating enzyme and
occurrence of renal diseases with chronic use of AAS.
AASs are commonly excreted in urine mainly as
glucuronide conjugates, the formation of which is cata-
lyzed by various uridine diphosphate-glucuronosyltrans-
ferase (UGT) enzymes. The UGTs 2B7, 2B15 and 2B17
are found to be the principal enzymes involved in
glucuronidation of androgens and their metabolites in
humans. Glucuronidation of steroids and their phase I
metabolites is an important detoxification and deactiva-
tion metabolic pathway which is catalyzed mainly by
UGT2B17 and to a minor extent by UGT2B15 [35-38]. In
2008, a few months before the Beijing Olympics, Schultze
and colleagues discovered that the occurrence of deletion
polymorphism in the gene coding of UGT2B17 enzyme
affected the urinary excretion patterns of testosterone
[18]. As the current doping testing regime relies on
detecting the steroid metabolites in urine, UGT2B17 defi-
cient drug abusers are likely to test negative despite the
use of the drug. Although the enzyme deficient athletes
who are aware of their own genetic profile may benefit
from evading doping testing, they may be vulnerable to
serious health consequences due to inadequate deactiva-
tion and elimination of steroids. The potential conse-
quences of this discovery has triggered the WADA and
sport governing bodies to examine their testing regimes.
However, it is inevitable that this phenomenon has sig-
nificant implications beyond the sporting arena. Juul et
al. [39] observed in pubertal boys, that the homozygous
deletion in the UGT2B17 gene, in line with Schulze et al.
[18], affected the urinary excretion pattern of androgen
metabolites, but not circulating androgen levels. A defi-
ciency of the UGT2B17 enzyme decreases the rate of ste-
roid deactivation and elimination, and owing to this, the
bioavailability of steroids may be enhanced to a certain
extent. Hence, elevated and prolonged use of AAS may
predispose the enzyme deficient individuals to detrimen-
tal effects, particularly relating to kidney damage.
Therefore, in this paper we hypothesise that the
observed renal disorders among AAS users is connected
to the genetic profiles of these users and functional poly-
morphic deletion of the UGT2B17 gene significantly
increases the chance of developing kidney complications.
Inter-individual variations in the frequency of UGT2B17 
gene deletion polymorphism
The occurrence of the UGT2B17 gene varies amongst
individuals of various ethnic groups. Wilson et al. carried
out a study on African Americans and the Caucasian
population, and found that the occurrence of deletion
mutation in the UGT2B17 gene was five time more fre-
quent in Caucasians than in African Americans [40].
Several comparative studies of urinary steroid concen-
trations amongst various ethnic groups have been
reported and it has been observed that individuals lack-
ing this enzyme have negligible excretion of steroids.
Sjöqvist et al. examined the association of androgen
excretion with UGT2B17 deletion in a population based
study comprising of Korean and Swedish participants
[22]. It was found that the absence of the UGT2B17 gene
was seven times more frequent in Koreans than in the
Swedish population. On examining the association
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androgens it was revealed that testosterone excretion was
16 times higher in Swedish people compared to the Kore-
ans. These findings indicate the importance of this gene
in the excretion of steroids.
Baume et al. reported inter-individual variations in the
excretion patterns and kinetics of nandrolone and its
metabolites after administration of [13C] nandrolone to
volunteers and noted the possible natural production of
nandrolone and its metabolites [20]. However, it can be
postulated that the variations in nandrolone excretion
could be due to variations in UGT2B17 genotypes
amongst individuals.
According to WADA guidelines, if the ratio of concen-
trations of testosterone to epitestosterone glucuronide in
urine is greater than 4, then drug doping is suspected
[41]. Since deletion polymorphism in the gene coding for
the UGT2B17 enzyme affects the urinary level of testos-
terone, the accuracy of the T/E ratio test is challenged. A
study carried out on a heterogeneous group of healthy
volunteers with different UGT2B17 genotypes (ins/ins,
ins/del and del/del) reported that administration of exog-
enous testosterone to individuals lacking the UGT2B17
gene did not yield T/E values above the population based
threshold of 4 for all individuals [18]. This is because the
testosterone glucuronide excretion rate in individuals
with del/del genotype was found to be significantly less
than those carrying the ins/del and ins/ins genotype. No
significant effect on epitestosterone excretion was
observed. The excretion of unconjugated steroid was
found to be a minor elimination pathway even in individ-
uals devoid of the gene. This indicates the possibility of
an increase in serum levels of biologically active steroids.
It has been reported previously that individuals of Asian
ethnicity excrete less testosterone which complements
the surveillance that the del/del genotype is more fre-
quent amongst the Asian population [18]. Many
researchers have observed similar difficulty in testing tes-
tosterone abuse pertaining to the UGT2B17 deletion, and
have suggested making use of genotype based cut-off lev-
els to overcome inter-individual and inter-ethnic varia-
tions [42].
These results indicate that a deletion polymorphism in
the gene coding is associated with urinary levels of ste-
roid glucuronide conjugates. Owing to an impaired
glucuronidation pathway, deactivation and elimination of
steroids is reduced. This may result in elevated serum lev-
els of active steroids which can be harmful over a long
period of time. Thus, specific groups of individuals who
are devoid of the UGT2B17 gene are more susceptible to
adverse health conditions due to chronic exposure to ele-
vated doses of steroids, compared to individuals having
the gene.
Concomitant use of drugs
UGTs not only contribute to AAS glucuronidation but
they also act as conjugating enzymes for various other
pharmaceutical drugs [35,43]. It has been reported that
athletes use AASs in combination with other medications
which may enhance the AAS effects and decrease the side
effects associated with such performance-enhancing
drugs. Co-administration of steroids along with other
UGT substrates may lead to competitive inhibition of ste-
roid glucuronidation. Sten et al. discovered that com-
monly used over-the-counter (OTC) non steroidal anti-
inflammatory drugs (NSAIDs) like diclofenac and ibu-
profen inhibited the testosterone glucuronidation activity
of UGT2B17, UGT2B15 and some other UGTs that have
previously shown low but detectable activity [43]. Com-
pared to UGT2B17, UGT2B15 was found to be more sen-
sitive to both the NSAIDs, particularly ibuprofen. Since,
UGT2B17 shares 96% homology with UGT2B15, in a
UGT2B17 deficient individual, UGT2B15 may be the
major contributor to glucuronidation. However, use of
steroids together with NSAIDs will competitively inhibit
the steroid glucuronidation activity of UGT2B15. The
inhibitory effect was also found to be dependent on the
UGT2B17 genotype. Regular use of such painkillers is
common amongst athletes in order to overcome the pain
associated with extensive exercise regimes [44]. Thus,
athletes devoid of the UGT2B17 gene are susceptible to
having complications in steroid elimination, as well as to
other medications administered simultaneously. Also,
such drug combinations can have direct deleterious
effects on renal health.
The occurrence of renal disorders among AAS users
Herlitz and colleagues reported a study on a cohort of
bodybuilders (white and hispanic) and observed that long
term use of anabolic steroids combined with high protein
intake was associated with proteinuria and secondary
focal segmental glomerulosclerosis (FSGS). The pattern
of glomerular injury observed, involves scarring of the
glomerules and is mediated by elevated glomerular filtra-
tion rate (hyperfiltration), glomerular pressure and other
adaptive structural-functional responses within the kid-
neys [29]. One of the bodybuilders with a history of occa-
sional urinary tract infection progressed to end stage
renal disease (ESRD) after prolonged use of AASs. It has
been reported that non obese individuals with increased
body mass index (BMI) owing to elevated muscle mass
are susceptible to developing secondary FSGS [29,45].
This indicates the possibility of developing serious renal
conditions after prolonged use of steroids by the gene
deficient individuals. Many researchers have also
reported other adverse renal conditions such as acute
kidney injury (AKI), nephropathy, diffuse type 1 mem-
branoproliferative glomerulonephritis and also renal fail-
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case studies, improvements in renal conditions have been
observed in patients who discontinued the use of ana-
bolic steroids. Also, acute renal failure has been reported
along with cholestatic liver damage after long term use of
AASs [32-34]. Disorders in the liver, the major site for
detoxification of steroids and other xenobiotics, can hin-
der its performance and hence worsen the renal condi-
tions due to elevated level of circulating toxins.
Presentation of the hypothesis
We hypothesize that with chronic and/or excessive use of
AAS, individuals with a deletion polymorphism in the
UGT2B17 gene (del/del) carry an increased risk of devel-
oping renal disorders owing to an increase in body mass
index and possible direct toxic effects of steroids on the
kidneys. Inadequate elimination of the biologically active
steroids will lead to elevated serum levels and cause sur-
plus increase in muscle mass. An increase in body mass
index may cause renal injuries due to sustained elevated
glomerular pressure and flow rate.
The fate of anabolic steroids in UGT2B17 deficient 
individuals
Once in the body, plasma protein binding and enzymatic
conversions of AASs regulate the availability of free and
active steroids at local target sites. Depending on the
chemical structure, steroids are deactivated primarily in
the liver by phase I (e.g., oxidation, reduction, or hydroxy-
lation) and phase II (glucuronide or sulphate conjugation)
metabolic reactions [46]. Glucuronidation by UGTs is
considered to be the major deactivation and elimination
pathway for steroids and their phase I metabolites. The
UGTs act by catalyzing the transfer of glucuronosyl group
from the uridine 5'-diphosphoglucuronic acid to the ste-
roid molecule. The resulting glucuronide drug conjugates
are less toxic, more polar, and hydrophilic in nature and
get easily excreted from the body in urine. The 3 α- and
17 β-OH positions of C-19 steroids and their metabolites
are the major sites involved in glucuronide conjugation
[35].
UGT2B17 catalyses glucuronidation at both oxygens
whereas UGT2B15 acts only at the 17 β-OH position,
hence it is less efficient than UGT2B17 in the elimination
of steroids. It can be argued that in individuals devoid of
the UGT2B17 gene, other UGTs like 1A1, 1A3, 1A4, 1A8,
1A9, 1A10, 2B4, 2B7, and 2B15 may contribute to steroid
glucuronidation [43,47]. But, less than normal produc-
tion of steroid glucuronides in individuals devoid of the
UGT2B17gene indicates inadequate efficiency of other
UGTs in eliminating steroids. Alternatively, it may be
expected that in order to compensate for impaired
glucuronidation activity, steroids may be excreted as sul-
phate conjugates. However, it was determined by Borts
and Bowers that individuals with del/del UGT2B17 geno-
types did not produce more than normal amounts of ste-
roid sulphate [48,49]. Also, the excretion of unconjugated
steroids in urine is considered to be a minor elimination
pathway, even in del/del individuals [18]. Thus, it can be
postulated that lipophilic, unconjugated steroids in the
systemic circulation may get distributed into body tis-
sues, get incorporated into the hair by endogenous route
or get excreted in sweat [50,51]. Drugs excreted in sweat
can further get absorbed by hair via endogenous-exoge-
nous pathways.
Since glucuronidation is the major pathway for deacti-
vation and elimination of steroids, UGT2B17 deficiency
may increase the serum level of biologically active ste-
roids and their metabolites. Thus, it can be postulated
that in UGT2B17 deficient individuals, chronic exposure
to AAS can result in high BMI and circulating levels of
proteins, relative to individuals with a functional enzyme.
Increase in body mass can force the kidneys to elevate the
glomerular filtration rate (hyperfiltration) and glomerular
pressure. Adaptive responses to sustained hyperfiltration
and elevated glomerular capillary pressures can lead to
the development of renal injuries like scarring of glomer-
ules, which may be associated with proteinuria due to ele-
vated circulating proteins. Hence, we postulate that
UGT2B17 gene homogeneous polymorphism (del/del)
increases the chance of developing renal disorders with
prolonged use of AAS due to increase in BMI and direct
toxic effect of steroids on kidneys.
Testing the hypothesis
As the hypothesis is based on the dysergistic effect of the
UGT2B17 polymorphism and long term exposure to
AAS, a single clinical trial approach does not present a
feasible way to generate evidence to support or refute the
hypothesis. Therefore an alternative, multi-component
approach is proposed with three distinct components: i)
delineation of single dose pharmacokinetics, ii) animal
model studies, and iii) genotype testing in humans suffer-
ing from renal failure.
To delineate single dose pharmacokinetics for com-
monly abused AAS, a population based study can be car-
ried out which involves the administration of a single
dose of a [13C] labelled AASs to healthy volunteers with
different UGT2B17 genotypes. Routine blood tests, bio-
fluid analyses, urinalysis and hair analyses [50,51] will
ascertain the deviation in the pharmacokinetics of ste-
roids owing to the prevalence of different UGT2B17 gen-
otypes. Thus, the circulating levels of active steroids (plus
phase I metabolites) and alternative metabolic pathways
of steroids in individuals with impaired glucuronidation
activity can be determined.
An animal study involving chronic administration of
AASs to mice or rats with different UGT2B17 genotypes,
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will help in scrutinizing the relationship between devel-
opment of renal disorders and deletion polymorphism in
the gene. In addition to affording AAS induced renal
impairment investigations, animal models will facilitate
controlled comparative pharmacokinetic studies of short
and long term AAS exposure in mice. In addition, these
data will allow comparison to the pharmacokinetics from
the human single dose study.
For clinical observations, patients with renal impair-
ment after long term use of anabolic steroids should be
analysed for genotype using real time PCR with allelic
discrimination to determine the prevalence of UGT2B17
deletion genotypes (del/del, ins/del and ins/ins). Studies
would also involve the evaluation of other UGTs which
have been reported to play a role in AAS glucuronidation
to accurately estimate the impact of each phenotype [52].
Thus, prospective or retrospective genotype analysis of
tissues from patients undergoing clinical treatments for
renal impairment with admitted steroid abuse are recom-
mended. In addition, depending on the pharmacokinetic
results from study i), analysis of hair samples could con-
firm cases of self-reported chronic AAS abuse.
Implications of the hypothesis
A system that is primarily based on detection-based
deterrence and sanctioning may be easily perceived as a
barrier to overcome if a competitive edge can be secured
by using performance-enhancing substances or methods.
Thus, the current repressive approach to anti-doping
inevitably leads to finding ways in detection evasion, with
health concerns being secondary. In this 'nothing or all'
system, the harm reduction approach that characterizes
many drug prevention programmes, cannot be accom-
modated.
Following the paper by Schulze and colleagues [18] on
the effect of UGT2B17 gene deletion polymorphism on
doping tests, it is likely that this discovery is turned into
practice and abused by athletes determined to use AAS.
In this scenario, athletes believe that they take the known
risk associated with AAS use, but not the risk of being
caught. However, if the hypothesis is correct, these ath-
letes expose themselves to an increased risk in developing
renal disorders as a consequence of their UGT2B17 gene
deletion polymorphism.
The harm reduction approach to doping, not yet offi-
cial but increasingly advocated among doping research-
ers [13,53], would benefit greatly from an empirical
verification of the assumption presented in this paper.
The potential danger present in this connection, a con-
trolled clinical trial with volunteers is not feasible but pri-
mary care physicians and nephrologists are in a
favourable position to advance our knowledge in this
area.
Although it has been recognized by now that education
based anti-doping prevention is a challenging task [54],
having objective information is the sine qua non of all
efforts relying on informed choice. This is not to advocate
the less effective loss-framed messages [55] or fear
appeals [56] in preventing AAS use, but rather to draw
attention to the fact that inter-individual variations in
metabolizing steroids could lead to serious health detri-
ments in individuals even at doses below the problematic
supraphysiological doses.
Groups that may benefit from this research are not only
AAS users who deliberately take advantage of their
unique genetic make-up to evade doping testing, hence
will face increased risk of developing renal complications,
but include other AAS users, such as recreational users
and bodybuilders unaware of the risk, who may inadver-
tently subject themselves to risks of developing kidney
disease. Beyond the athletic arena, administration of AAS
should be avoided for patients with nephritic symptoms
as it may worsen renal conditions. AAS have been found
to be beneficial in improving conditions of individuals
with muscle wasting disorders. Researchers have
observed improvement in lean body mass of individuals
with HIV and chronic obstructive pulmonary disease
(COPD) after administration of AAS [27]. Thus, AAS, if
not misused, can have therapeutic applications. However,
patients that are devoid of the gene will be more vulnera-
ble to serious health consequences. As pharmacokinetic
investigations are a key part of the proposed hypothesis
testing studies, additional information will be generated
on inter-individual differences which may have implica-
tions beyond the hypothesis. In such situations, alterna-
tive treatment should be employed or a genotype based
safe dose should be identified.
List of abbreviations
AASs: Anabolic androgenic steroids; AKI: Acute kidney
injury; BMI: Body mass index; COPD: Chronic obstruc-
tive pulmonary disease; ESRD: End stage renal disease;
FSGS: Focal segmental glomerulosclerosis; HDL: High
density lipoprotein; HIV: Human immunodeficiency
virus; LDL: Low density lipoprotein; T/E: Testosterone to
epitestosterone ratio; UGT2B15: Uridine diphosphate-




The authors declare that they have no competing interests.
Authors' contributions
AP conceived the study. All authors have contributed equally to formulating
the hypothesis. ND, AP and DPN have drafted the paper. All authors have read
and approved the final version of the manuscript.
Deshmukh et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:7
http://www.substanceabusepolicy.com/content/5/1/7
Page 6 of 7Author Details
1School of Pharmacy and Chemistry, Kingston University, London, UK, 2School 
of Life Sciences, Kingston University, London, UK and 3Department of 
Anatomy, Histology and Embryology, Semmelweis University of Medicine, 
Budapest IX, Tüzoltó utca 58, H-1450, Hungary
References
1. World Anti-Doping Agency, 2009. World Anti-doping Code 2009   
[http://www.wada-ama.org/Documents/Anti-Doping_Community/
WADA_Anti-Doping_CODE_2009_EN.pdf]
2. Fraser AD: Doping control from a global and national perspective.  Ther 
Drug Monit 2004, 26(2):171-174.
3. Catlin DH, Fitch KD, Ljungqvist A: Medicine and science in the fight 
against doping in sport.  J Intern Med 2008, 264(2):99-114.
4. Mangan JA, Majumdar B: Doping in sport, global ethical issues.  In Sports 
in global society Edited by: Schneider AJ, Hong F. Routledge; 2007. 
5. Tamburini C: Are doping sanctions justified? a moral realistic view.  Sp 
Society 2006, 9(2):199-211.
6. Anderson L: Writing a new code of ethics for sports physicians: 
principles and challenges.  Br J Sports Med 2009, 43:1079-1082.
7. McNamee M, Phillips N: Confidentiality, disclosure and doping in sports 
medicine.  Br J Sports Med 2009. doi:10.1136/bjsm.2009.064253.
8. McNamee MJ, Arno M, Hilvoorde I, Holm S: Genetic testing and sports 
medicine ethics.  Sports Med 2009, 39(5):339-344.
9. Hilderbrand R: The world anti-doping program and the primary care 
physician.  Pediatr Clin North Am 2007, 54(4):701-711.
10. Lippi G, Banfi G, Franchini M: The international anti-doping system: why 
it might not work.  Clin Chim Acta 2009, 408(1-2):141-142.
11. Kayser B, Mauron A, Miah A: Current anti-doping policy: a critical 
appraisal.  BMC Med Ethics 2007, 8:2. doi:10.1186/1472-6939-8-2
12. Kayser B, Smith ACT: Globalisation of anti-doping: the reverse side of 
the medal.  BMJ 2008, 337:85-87.
13. Smith AC, Stewart B: Drug policy in sport: hidden assumptions and 
inherent contradictions.  Drug Alcohol Rev 2008, 27(2):123-129.
14. Hanstad DV, Loland S: Elite athletes' duty to provide information on 
their whereabouts: justifiable anti-doping work or an indefensible 
surveillance regime?  Europ J Sport Sci 2009, 9(1):3-10.
15. Park JK: Governing doped bodies: the world anti-doping agency and 
the global culture of surveillance.  Cult Stud Cr Methodol 2005, 
5(2):174-188.
16. Trout GJ, Kazlauskas R: Sports drug testing--an analyst's perspective.  
Chem Soc Rev 2004, 33(1):1-13.
17. Lippi G, Franchini M, Guidi GC: Doping in competition or doping in 
sport?  Br Med Bull 2008, 86(1):95-107.
18. Schulze JJ, Lundmark J, Garle M, Skilving , Ekström L, Rane A: Doping test 
results dependent on genotype of uridine diphospho-glucuronosyl 
transferase 2B17, the major enzyme for testosterone glucuronidation.  
J Clin Endocrinol Metab 2008, 93(7):2500-2506.
19. Kicman AT, Cowan DA: Subject-based profiling for the detection of 
testosterone administration in sport.  Drug Test Analysis 2009, 1(1):22-24.
20. Baume N, Avois L, Schweizer C, Cardis C, Dvorak J, Cauderay M, Mangin P, 
Saugy M: [13C]Nandrolone excretion in trained athletes: interindividual 
variability in metabolism.  Clin Chem 2004, 50:355-364.
21. Kicman AT: Pharmacology of anabolic steroids.  Br J Pharmacol 2008, 
154(3):502-521.
22. Sjöqvist F, Garle M, Rane A: Use of doping agents, particularly anabolic 
steroids, in sports and society.  Lancet 2008, 371(9627):1872-1882.
23. Graham MR, Davies B, Grace FM, Kicman A, Baker JS: Anabolic steroid use: 
patterns of use and detection of doping.  Sports Med 2008, 
38(6):505-525.
24. Kanayama G, Hudson JI, Pope HG Jr: Long-term psychiatric and medical 
consequences of anabolic-androgenic steroid abuse: a looming public 
health concern?  Drug Alcohol Depend 2008, 98(1-2):1-12.
25. Harmer PA: Anabolic-androgenic steroid use among young male and 
female athletes: is the game to blame?  Br J Sports Med 2010, 44:26-31.
26. Wood RI: Anabolic-androgenic steroid dependence? insights from 
animals and humans.  Front Neuroendocrinol 2008, 29(4):490-496.
27. Shahidi NT: A review of the chemistry, biological action, and clinical 
applications of anabolic-androgenic steroids.  Clin Ther 2001, 
23(9):1355-1390.
28. Hartgens F, Kuipers H: Effects of androgenic-anabolic steroids in 
athletes.  Sports Med 2004, 34(8):513-554.
29. Herlitz L, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, 
Colvin RB, D'Agati VD: Development of focal segmental 
glomerulosclerosis after anabolic steroid abuse.  J Am Soc Nephrol 2010, 
21:163-172.
30. Daher EF, Silva Júnior GB, Queiroz AL, Ramos LM, Santos SQ, Barreto DM, 
Guimarães AA, Barbosa CA, Franco LM, Patrocínio RM: Acute kidney 
injury due to anabolic steroid and vitamin supplement abuse: report of 
two cases and a literature review.  Int Urol Nephrol 2009, 41(3):717-723.
31. Révai T, Sápi Z, Benedek S, Kovács A, Kaszás I, Virányi M, Winkler G: Severe 
nephritic syndrome in a young man taking anabolic steroid and 
creatine long term.  Orv Hetil 2003, 144(49):2425-2427.
32. Habscheild W, Abele U, Dahm HH: Severe cholestasis with kidney failure 
from anabolic steroids in a body builder.  Dtsch Med Wochenschr 1999, 
124(36):1029-1032.
33. Nasr J, Ahmad J: Severe cholestasis and renal failure associated with the 
use of the designer steroid Superdrol (methasteron): a case report and 
literature review.  Dig Dis Sci 2009, 54(5):1144-1146.
34. Krishnan PV, Feng ZZ, Gordon SC: Prolonged intrahepatic cholestasis 
and renal failure secondary to anabolic androgenic steroid-enriched 
dietary supplements.  J Clin Gastroenterol 2009, 43(7):672-675.
35. Turgeon D, Carrier JB, Chouinard S, Belanger A: Glucuronidation activity 
of the UGT2B17 enzyme toward xenobiotics.  Drug Metab Dispos 2003, 
31:670-676.
36. Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S: Inactivation of 
androgens by UDP-glucuronosyltransferase enzymes in humans.  
Trends Endocrinol Metab 2003, 14(10):473-479.
37. Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C, Vallee 
M, Guillemette C, Tchernof A, Turgeon D, Dubois S: Characterization of 
UDP-glucuronosyltransferases active on steroid hormones.  J Ster 
Biochem Mol Biol 1999, 69:413-423.
38. You L: Steroid hormone biotransformation and xenobiotic induction of 
hepatic steroid metabolizing enzymes.  Chem Biol Interact 2004, 
147:233-246.
39. Juul A, Sørensen K, Aksglaede L, Garn I, Rajpert-De Meyts E, Hullstein L, 
Hemmersbach P, Ottesen AM: A common deletion in the uridine 
diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong 
determinant of androgen excretion in healthy pubertal boys.  J Clin 
Endocrinol Metab 2009, 94(3):1005-1011.
40. Wilson W, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, 
Detwiler AD, Gilmore RC, Valladeras IC, Wright CC, Threadgill DW, Delores 
GJ: Characterization of a common deletion polymorphism of the 
UGT2B17 gene linked to UGT2B15.  Genomics 2004, 84:707-714.
41. WADA Technical Document-TD2004EAAS   [http://www.wada-ama.org/
rtecontent/document/end_steroids_aug_04.pdf]
42. Strahm E, Sottas PE, Schweizer C, Saugy M, Dvorak J, Saudan C: Steroid 
profiles of professional soccer players: an international comparative 
study.  Br J Sports Med 2009, 43(14):1126-1130.
43. Sten T, Finel M, Ask B, Rane A, Ekström L: Non-steroidal anti-
inflammatory drugs interact with testosterone glucuronidation.  
Steroids 2009, 74:971-977.
44. Skårberg K, Nyberg F, Engström I: The development of multiple drug use 
among anabolic-androgenic steroid users: six subjective case reports.  
Subst Abuse Treat Prev Policy 2008, 3:24. doi: 10.1186/1747-597X-324
45. Schwimmer JA, Markowitz GS, Valeri AM, Imbriano LJ, Alvis R, D'Agati VD: 
Secondary focal segmental glomerulosclerosis in non-obese patients 
with increased muscle mass.  Clin Nephrol 2003, 60(4):233-241.
46. Schanzer W: Metabolism of anabolic androgenic steroids.  Clin Chem 
1996, 42(7):1001-1020.
47. Kuuranne T, Kurkel M, Thevis M, Schänzer W, Finel M, Kotiainen : 
Glucuronidation of anabolic androgenic steroids by recombinant 
human UDP-glucuronosyl transferases.  Drug Metab Dispos 2003, 
31:1117-1124.
48. Bowers LD: Testosterone Doping: Dealing with Genetic Differences in 
Metabolism and Excretion.  J Clin Endocrinol Metab 2008, 
93(7):2469-2471.
49. Borts DJ, Bowers LD: Direct measurement of urinary testosterone and 
epitestosterone conjugates using high-performance liquid 
Received: 9 February 2010 Accepted: 29 April 2010 
Published: 29 April 2010
This article is available from: http://www.substanceabusepolicy.com/content/5/1/7© 2010 D shmukh et al; licensee BioMed Central Ltd. is an Open Acc ss article distribut under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Substan e Abuse Treatment, Pr vention, and Policy 2010, 5:7
Deshmukh et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:7
http://www.substanceabusepolicy.com/content/5/1/7
Page 7 of 7chromatography/tandem mass spectrometry.  J Mass Spectrom 2000, 
35:50-61.
50. Gaillard Y, Pepin G: Testing hair for pharmaceuticals.  J Chromatogr B 
1999, 733:231-246.
51. Anielski P: Hair analysis of anabolic steroids in connection with doping 
control-results from horse samples.  J Mass Spectrom 2008, 
43:1001-1008.
52. Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, 
Karlsson M, Ljunggren O, Smith U, Eriksson AL, Bélanger A, Labrie F, 
Ohlsson C: The uridine diphosphate glucuronosyltransferase 2B15 
D85Y and 2B17 deletion polymorphisms predict the glucuronidation 
pattern of androgens and fat mass in men.  Clin Endocrinol Metab 2007, 
92(12):4878-4882.
53. Lippi G, Banfi G, Franchini M, Guidi GC: New strategies for doping 
control.  J Sports Sci 2008, 26(5):441-445.
54. Hanson JM: Equipping athletes to make informed decision about 
performance-enhancing drug use: a constructivist perspective from 
educational psychology.  Sp Society 2009, 12(3):394-410.
55. O'Keefe DJ, Jensen JD: The relative persuasiveness of gain-framed and 
loss-framed messages for encouraging disease prevention behaviour: 
a meta analytic review.  J Health Commun 2007, 12(7):623-644.
56. Witte K, Allen M: A meta-analysis of fear appeals: implications for 
effective public health campaigns.  Health Educ Behav 2000, 
27(5):591-615.
doi: 10.1186/1747-597X-5-7
Cite this article as: Deshmukh et al., Potentially harmful advantage to ath-
letes: a putative connection between UGT2B17 gene deletion polymor-
phism and renal disorders with prolonged use of anabolic androgenic 
steroids Substance Abuse Treatment, Prevention, and Policy 2010, 5:7
